← Back
FeaturedOncologyASCO 20262 endpoints open for prediction

Monjuvi (tafasitamab)

Incyte / MorphoSys

Anti-CD19 MAb + lenalidomide + R-CHOP vs R-CHOP in 1L DLBCL. FRONTMIND Phase 3 toplined positive January 2026 — primary EFS endpoint hit, details not disclosed. Full data at ASCO 2026 late-breaker LBA7000 (June 1). Key prediction events: EFS hazard ratio magnitude and whether OS shows early separation. If confirmed, would establish tafasitamab in frontline DLBCL; currently only approved in R/R setting.

Diffuse Large B-Cell Lymphoma1st-line
2
Open endpoints

Live Predictions

Hazard Ratio for Event-Free Survival (EFS)PRIMARY

AA Hazard Ratio below 1.0 favours tafasitamab + lenalidomide + R-CHOP. The primary endpoint of FRONTMIND. Toplined positive January 2026 — full HR data at ASCO 2026 LBA7000.

Range: 0.4 – 0.9 Hazard Ratio
Predict →
Readout TBD
Loading…
Hazard Ratio for Overall Survival (OS)

A Hazard Ratio below 1.0 favours the treatment arm. HR 0.75 means a 25% reduction in the risk of death.

Range: 0.4 – 1.2 Hazard Ratio
Predict →
Readout TBD
Loading…
Loading comments…

Also Known As

Other names

tafasitamab
Search all trials →Request coverage update